Biocon’s latest licensing agreement with Janssen Sciences Ireland is expanding the international commercial reach of a proposed biosimilar medicine, highlighting the value of cross-border partnerships in pharmaceutical development. Announced on 26 October 2026, the agreement gives Biocon rights to commercialise Yesintek, its biosimilar to Stelara, in nine additional markets, extending the company’s reach across major pharmaceutical territories.

The agreement covers Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan. It builds on earlier arrangements establishing market-entry dates in the United States, Europe, the UK, Canada and Japan. As reported by Express Pharma, the deal broadens Biocon’s commercialisation framework for ustekinumab, although launches in the newly covered markets remain subject to local regulatory approval.

Biocon is an India-based biopharmaceutical company specialising in biosimilars, generic medicines and active pharmaceutical ingredients. Janssen Sciences Ireland, part of Johnson & Johnson’s pharmaceutical business, is the licensing partner in the agreement. Their collaboration demonstrates how pharmaceutical companies can use licensing arrangements to establish routes into international markets, combining product development capabilities with negotiated commercial access.

Yesintek is a biosimilar to Stelara, whose active ingredient, ustekinumab, targets interleukin-12 and interleukin-23 pathways involved in immune-mediated conditions. These include Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. According to Johnson & Johnson’s 2025 financial results, Stelara generated $6.078 billion in worldwide sales during 2025, illustrating the commercial scale of the reference medicine and the market opportunity for biosimilar competition.

For pharmaceutical manufacturers and commercial partners, the agreement highlights the importance of coordinating licensing, regulatory submissions, market access and supply planning across multiple jurisdictions. Securing commercial rights is a significant step, but successful launches also depend on national approvals, local requirements and reliable product supply. Biocon has not disclosed the financial terms or specific launch dates for the nine additional markets.

The announcement also reinforces Ireland’s role in international pharmaceutical business relationships. While no new Irish investment or jobs were announced, Janssen Sciences Ireland’s participation demonstrates how Irish-based pharmaceutical entities can contribute to agreements with global commercial reach. Biocon’s official announcement confirms the nine markets and the requirement for local regulatory approvals before launch.

For the sector, the lesson is direct: pharmaceutical growth increasingly depends on partnerships that connect product development with regulatory access and global commercialisation. By extending Yesintek’s licensing footprint, Biocon is creating further opportunities to compete in international biosimilar markets and broaden potential treatment options for patients.

Source: Express Pharma / Biocon / Johnson & Johnson